A Phase 2 interventional study of SST-0225 and Placebo in Delayed Onset Muscle Soreness, sponsored by Strategic Science & Technologies, LLC. Completed at 2 sites in United States. Open to participants aged 16 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-09-09.
Sponsored by Strategic Science & Technologies, LLC · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Myalgia with a site in United States — 13 open to participants now, 15 under way, none of them phase 3. Myalgia · United States.
Among the 86 studies in Myalgia with a site in United States, this one is the 25th largest by enrollment of the 77 interventional ones that give a count, is one of 4 that started in 2014, is one of 10 in phase 2, and was the 29th registered.
256 studies on the registry are indexed under Myalgia; 46 are open to participants now.
Browse Myalgia studies →13 of the 86 studies in Myalgia with a site in United States are open now. Recruiting first, the newest first:
Applied Science & Performance Institute · Sites in United States
Ages 20–55 · Men only · Healthy volunteers
Sam Houston State University · Sites in United States
Ages 18–60 · Healthy volunteers
Sam Houston State University · Sites in United States
Ages 18–60 · Healthy volunteers
University of Minnesota · Sites in United States
Ages 18–30 · Healthy volunteers
ESM Technologies, LLC · Sites in United States
Ages 18–40 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 27 Myalgia studies recruiting now, 6 (22%) set no upper age limit and 20 (74%) stop at 75 or younger; 4 take children under 18; 17 take healthy volunteers.
This study: 16 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 13 · Phase 3 11 · Phase 4 7
First in 2002; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is above the median of 44 across 216 interventional studies indexed under Myalgia.
Median enrollment 40 across the 77 interventional studies, 250 across the 9 observational. Of the 65 that completed or were terminated, 17 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 86 have an industry lead sponsor. The 10 most frequent:
Strategic Science & Technologies, LLC is the lead sponsor of 9 studies on the registry; none are open to participants now.
Strategic Science & Technologies, LLC has 2 studies filed under Myalgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Myalgia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07822048Sam Houston State UniversityEffects of Beef-Forward Ready-to-Eat Meals on Recovery Following Simulated Fire Suppression Activities | 2026-11-30 |
| NCT07819565Sam Houston State UniversityEffects of Pork Protein on Recovery Following Simulated Fireground Activity | 2026-11-30 |
| NCT07219498University of MinnesotaEffects of a 5-Week Probiotic Supplementation Intervention on Markers of Delayed Onset Muscle Soreness | 2026-12-31 |
| NCT07756658Applied Science & Performance InstituteThe Effects of Tyrosol and Creatine on Exercise Performance and Cognition in Healthy Adults | 2027-01-17 |
| NCT04128670Indiana UniversityEffects of Kinesio Tape on Delayed Onset Muscle Soreness | 2027-05-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 86 studies in Myalgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the dosing interval, efficacy and safety of SST-0225 (5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain associated with DOMS.
This is a Phase 2, prospective, randomized, dual-center, double-blind, placebo-controlled, parallel-group study designed to determine the dosing interval, efficacy and safety of SST-0225 (5.4 grams, applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain associated with DOMS.
As part of the screening process, in the evening of Day -2, eligible subjects will undergo an exercise regimen designed to induce DOMS in the elbow flexor of the non-dominant arm (see Section 11). 36 (±2) hours following the exercise regimen, subjects will return to the clinic and be evaluated for eligibility into the active treatment phase of the study. Eligible subjects who experience a sufficient level of pain 36 (± 2) hours after exercise will be randomized to receive either SST-0225 or placebo.
For the first 24 hour dosing period, the subject will remain in the clinic (on-site). Subjects will apply the first dose of Investigational Product (IP) at randomization (0 hours) and a second dose upon request (PRN or as needed). All subsequent doses will be applied every 5 (±1) hours. The total number of doses shall not exceed 6 in this first 24 hour period. Subjects will also not be allowed to take any rescue medication during the first 24 hour dosing period.
Subjects will complete the Visual Analog Scale (VAS) pain/soreness on movement assessments at the following time points while on-site the first 24 hours: 0 (prior to first dose of IP), 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14, 16, and 24 hours post first dose of IP and immediately prior to the second dose of IP. All assessments must be completed unless the subject is asleep. Subjects will be restricted to a maximum of 8 hours of sleep in order to limit the number of missing VAS pain/soreness on movement assessments due to sleep. Immediately upon wakening on Day 2, subjects will be instructed to apply a dose of IP unless it has been less than 5 (±1) hours since their last dose of IP.
After subjects complete their 24 hour VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the second 24 hour dosing period.
During the second 24 hour dosing period (24-48 hours post first dose of IP), the subject will be away from the clinic (off-site) and will apply the IP every 5 (±1) hours. The total number of doses shall not exceed 6 doses in this second 24 hour period. Rescue medication will be made available to subjects during this second 24 hour period. During this second 24 hour period, subjects will complete the VAS pain/soreness on movement assessment prior to each IP dose and at 1 hour post each dose of IP.
Refer to the Schedule of Evaluations in Appendix A (on-site evaluations) and Appendix B (off-site evaluations) for details regarding the timing of study procedures.
Healthy male and female subjects between 16 and 65 years of age.
Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
Drug: SST-0225
Subjects will be treated with IP for 48 hours. While on-site, subjects will apply the first dose of IP at 0 hours, the second dose upon request (PRN), and all subsequent doses every 5 (±1) hours, up to a maximum of 6 doses in 24 hours. After subjects complete their 24 hour post first dose VAS pain/soreness on movement assessment, they will be released from the clinic and will continue outpatient treatment for the remaining 24 hours. While off-site subjects will dose every 5 (±1) hours, not to exceed 6 doses in 24 hours.
Drug: Placebo
SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
Also known as: Topical Ibuprofen Cream
Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
SPID24 (calculated by summing the time weighted VAS pain/soreness on movement assessment differences from baseline)
The primary efficacy endpoint will be the time weighted summed pain/soreness intensity difference from baseline VAS pain/soreness on movement assessments over the first 24 hours (SPID24) following the first application of IP on Day 1. SPID24 will be calculated by summing the time weighted VAS pain/soreness on movement assessment differences from baseline (pre-dose on Day 1) to 24 hours (using actual reported VAS assessment times) post first dose of IP on Day 1.
Time frame: First 24 hours after first dose
Plan to share: Undecided
No publications or documents are linked to this record.
The record gives a start of Nov 2014, a primary completion of Feb 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Strategic Science & Technologies, LLC